Sagimet Biosciences Shares Climb on Acne Treatment's Trial Results

Dow Jones10-24

By Katherine Hamilton

Sagimet Biosciences shares rose after the company's acne treatment met all primary and secondary endpoints in a phase 3 trial.

The stock gained 17% to $8.55 Friday. Shares are up 87% this year.

The primary endpoints for denifanstat, a once-daily oral treatment for moderate to severe acne, included the percentage of treatment success, the percentage change in total lesion count and the percentage change in inflammatory lesion count.

The treatment also was generally well tolerated in the trial, which included 480 patients.

Earlier in October, Sagimet's partner Ascletis said it completed a pre-new drug application consultation with the China National Medical Products Administration. It plans to submit an application soon.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

October 24, 2025 11:48 ET (15:48 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577354326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577354326","market":"hk","top_or_hot":-1,"title":"Sagimet Biosciences Shares Climb on Acne Treatment's Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> shares rose after the company's acne treatment met all primary and secondary endpoints in a phase 3 trial. \n</p>\n<p>\n  The stock gained 17% to $8.55 Friday. Shares are up 87% this year. \n</p>\n<p>\n  The primary endpoints for denifanstat, a once-daily oral treatment for moderate to severe acne, included the percentage of treatment success, the percentage change in total lesion count and the percentage change in inflammatory lesion count. \n</p>\n<p>\n  The treatment also was generally well tolerated in the trial, which included 480 patients. \n</p>\n<p>\n  Earlier in October, Sagimet's partner Ascletis said it completed a pre-new drug application consultation with the <a href=\"https://laohu8.com/S/688128\">China National</a> Medical Products Administration. It plans to submit an application soon. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 11:48 ET (15:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Shares Climb on Acne Treatment's Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Shares Climb on Acne Treatment's Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-24 23:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> shares rose after the company's acne treatment met all primary and secondary endpoints in a phase 3 trial. \n</p>\n<p>\n  The stock gained 17% to $8.55 Friday. Shares are up 87% this year. \n</p>\n<p>\n  The primary endpoints for denifanstat, a once-daily oral treatment for moderate to severe acne, included the percentage of treatment success, the percentage change in total lesion count and the percentage change in inflammatory lesion count. \n</p>\n<p>\n  The treatment also was generally well tolerated in the trial, which included 480 patients. \n</p>\n<p>\n  Earlier in October, Sagimet's partner Ascletis said it completed a pre-new drug application consultation with the <a href=\"https://laohu8.com/S/688128\">China National</a> Medical Products Administration. It plans to submit an application soon. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 11:48 ET (15:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMT","symbol_name":"Sagimet Biosciences Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577354326","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577354326","pubTimestamp":1761320880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sagimet Biosciences shares rose after the company's acne treatment met all primary and secondary endpoints in a phase 3 trial.The stock gained 17% to $8.55 Friday. Shares are up 87% this year.The primary endpoints for denifanstat, a once-daily oral treatment for moderate to severe acne, included the percentage of treatment success, the percentage change in total lesion count and the percentage change in inflammatory lesion count.The treatment also was generally well tolerated in the trial, which included 480 patients.Earlier in October, Sagimet's partner Ascletis said it completed a pre-new drug application consultation with the China National Medical Products Administration. It plans to submit an application soon.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGMT":"Sagimet Biosciences Inc.","BK4139":"生物科技"},"translate_title":"Sagimet Biosciences股价因痤疮治疗试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\nSagimet Biosciences shares rose after the company's acne treatment met all primary and secondary endpoints in a phase 3 trial. \n\n\n  The stock gained 17% to $8.55 Friday. Shares are up 87% this year. \n\n\n  The primary endpoints for denifanstat, a once-daily oral treatment for moderate to severe acne, included the percentage of treatment success, the percentage change in total lesion count and the percentage change in inflammatory lesion count. \n\n\n  The treatment also was generally well tolerated in the trial, which included 480 patients. \n\n\n  Earlier in October, Sagimet's partner Ascletis said it completed a pre-new drug application consultation with the China National Medical Products Administration. It plans to submit an application soon. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 24, 2025 11:48 ET (15:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577354326","isCrawlerRequest":true}